Display options
Cite
Barata P, Hatton W, Desai A, et al. Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. Front Oncol. 2020;10:581189doi: 10.3389/fonc.2020.581189.
Barata, P., Hatton, W., Desai, A., Koshkin, V., Jaeger, E., Manogue, C., Cotogno, P., Light, M., Lewis, B., Layton, J., Sartor, O., Basu, A., Kilari, D., Emamekhoo, H., & Bilen, M. A. (2020). Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. Frontiers in oncology, 10581189. https://doi.org/10.3389/fonc.2020.581189
Barata, Pedro, et al. "Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort." Frontiers in oncology vol. 10 (2020): 581189. doi: https://doi.org/10.3389/fonc.2020.581189
Barata P, Hatton W, Desai A, Koshkin V, Jaeger E, Manogue C, Cotogno P, Light M, Lewis B, Layton J, Sartor O, Basu A, Kilari D, Emamekhoo H, Bilen MA. Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. Front Oncol. 2020 Oct 22;10:581189. doi: 10.3389/fonc.2020.581189. eCollection 2020. PMID: 33194712; PMCID: PMC7642690.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2020 Oct 22;10:581189. doi: 10.3389/fonc.2020.581189. eCollection 2020.

Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort.

Frontiers in oncology

Pedro Barata, Whitley Hatton, Arpita Desai, Vadim Koshkin, Ellen Jaeger, Charlotte Manogue, Patrick Cotogno, Malcolm Light, Brian Lewis, Jodi Layton, Oliver Sartor, Arnab Basu, Deepak Kilari, Hamid Emamekhoo, Mehmet A Bilen

Affiliations

  1. Deming Department of Medicine, Tulane University Medical School, New Orleans, LA, United States.
  2. Department of Medicine, University of California, San Francisco, San Francisco, CA, United States.
  3. Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
  4. Department of Medicine, Medical College of Wisconsin Cancer Center, Milwaukee, WI, United States.
  5. Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, WI, United States.
  6. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, United States.

PMID: 33194712 PMCID: PMC7642690 DOI: 10.3389/fonc.2020.581189

[No abstract available.]

Copyright © 2020 Barata, Hatton, Desai, Koshkin, Jaeger, Manogue, Cotogno, Light, Lewis, Layton, Sartor, Basu, Kilari, Emamekhoo and Bilen.

Keywords: PD-1/PD-L1 inhibitor; first-line treatment; immunotherapy; metastatic renal cell carcinoma; monotherapy

References

  1. N Engl J Med. 2015 Nov 5;373(19):1803-13 - PubMed
  2. N Engl J Med. 2018 Apr 05;378(14):1277-1290 - PubMed
  3. Br J Cancer. 2018 Jul;119(2):160-163 - PubMed
  4. J Clin Oncol. 2020 Oct 27;:JCO2002295 - PubMed
  5. Eur Urol Oncol. 2019 Nov 27;: - PubMed
  6. Cancer. 2008 Oct 1;113(7):1641-8 - PubMed
  7. Lancet Oncol. 2019 Oct;20(10):1386-1394 - PubMed
  8. Clin Genitourin Cancer. 2017 Aug;15(4):e573-e582 - PubMed
  9. J Immunother Cancer. 2018 Jan 29;6(1):9 - PubMed
  10. Lancet. 2019 Jun 15;393(10189):2404-2415 - PubMed
  11. CA Cancer J Clin. 2020 Jan;70(1):7-30 - PubMed
  12. CA Cancer J Clin. 2017 Nov;67(6):507-524 - PubMed
  13. J Clin Oncol. 2009 Dec 1;27(34):5794-9 - PubMed
  14. N Engl J Med. 2019 Mar 21;380(12):1116-1127 - PubMed
  15. J Clin Oncol. 2020 Jan 1;38(1):63-70 - PubMed
  16. N Engl J Med. 2019 Mar 21;380(12):1103-1115 - PubMed
  17. J Immunother. 2019 Nov/Dec;42(9):350-353 - PubMed

Publication Types

Grant support